Showing 2831-2840 of 5258 results for "".
- US FDA Grants Orphan Drug Status to TXA127 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/us-fda-grants-orphan-drug-status-to-txa127-for-recessive-dystrophic-epidermolysis-bullosa/2458442/The U.S. Food and Drug Administration has granted Orphan Drug Status to TXA127 as a potential treatment for the rare genetic skin disorder Recessive Dystrophic Epidermolysis Bullosa (RDEB). TXA127 developer, Tarix Orphan LLC
- Vivacare and the National Rosacea Society Collaborate on Patient Education Resourcehttps://practicaldermatology.com/news/vivacare-and-the-national-rosacea-society-collaborate-on-patient-education-resource/2458448/Vivacare has launched a new Rosacea Education Kit to support dermatologists in the delivery of care to their rosacea patients. The Kit is available at no cost by enrolling online. Upon enrolling, dermatologists receive
- FDA Approves Enbrel Biosimilarhttps://practicaldermatology.com/news/fda-approves-enbrel-biosimilar/2458451/The U.S. Food and Drug Administration (FDA) approved Erelzi for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. The move is no surprise given the unanimous backing of an FDA advisory arm last month. There are now
- Face-Aging App May Encourage Sun-Safe Behaviorhttps://practicaldermatology.com/news/face-aging-app-may-encourage-sun-safe-behavior/2458460/Appealing to their vanity may be the best way to encourage young women to practice sun-safe behaviors, a new study shows. The new research, published in
- Dr. Reddy's Sernivo Officially Debuts at NYC Media Eventhttps://practicaldermatology.com/news/dr-reddys-sernivo-officially-debuts-at-nyc-event/2458473/Calling Sernivo (betamethasone dipropionate) Spray 0.05% a ‘trifecta’ for dermatologists who treat mild-to-moderate psoriasis, Josh Zeichner, MD, introduced members of the New York City media to the new spray-on steroid. “It is effe
- Mission Pharmacal Expands Dermatology Commitment with the Acquisition of GlyDermhttps://practicaldermatology.com/news/mission-pharmacal-expands-dermatology-commitment-with-the-acquisition-of-glyderm/2458487/Espada Dermatology, Inc, a wholly-owned subsidiary of Mission Pharmacal Company, purchased the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC. Prior to this acquisition, Mission offered prescription dermatological products solely through Mission Dermatology
- Revance's Injectable Toxin to Enter Phase 3 Trialshttps://practicaldermatology.com/news/revances-injectable-toxin-to-enter-phase-3-trials/2458500/It’s game on for Revance Therapeutics, Inc. The company expects to initiate Phase 3 clinical trials of Injectable DaxibotulinumtoxinA (RT002) for the treatment of glabellar lines in the second half of 2016. Revance is moving forward with an
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),
- Daily ‘Soak and Smear' OKed for Kids with Eczemahttps://practicaldermatology.com/news/daily-soak-and-smear-oked-for-kids-with-eczema/2458513/Daily bathing is fine for children with eczema as long as it's followed by lots of moisturizer, according to a new article in Annals of Allergy, Asthma and Immunology. Researchers led by Portl
- Analysis Uncovers Health Economic Data for H.P. Acthar® Gel in Dermatomyositis and Polymyositishttps://practicaldermatology.com/news/analysis-uncover-health-economic-data-for-hp-acthar-gel-in-dermatomyositis-and-polymyositis/2458519/Results from two retrospective analyses sponsored by Mallinckrodt plc show that use of the company’s H.P. Acthar® Gel (repository corticotropin injection) offers a cost-effec